Sep26 Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Sep26 Quarterly Activities Report
- Removal of draft wording in the directors report HY accounts
- Jun26 Appendix 4C Cash Flow Report
- Update on Funding Facility and Clinical Program
- Binding Letter of Intent to replace existing $53m facility
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics